193 related articles for article (PubMed ID: 20680707)
1. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts.
Guerrieri P; Rumondor AC; Li T; Taylor LS
AAPS PharmSciTech; 2010 Sep; 11(3):1212-22. PubMed ID: 20680707
[TBL] [Abstract][Full Text] [Related]
2. Impact of counterion on the chemical stability of crystalline salts of procaine.
Guerrieri P; Jarring K; Taylor LS
J Pharm Sci; 2010 Sep; 99(9):3719-30. PubMed ID: 19967781
[TBL] [Abstract][Full Text] [Related]
3. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
David SE; Timmins P; Conway BR
Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the influence of counterion on the properties of some amorphous organic salts.
Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
[TBL] [Abstract][Full Text] [Related]
5. The Selection of a Pharmaceutical Salt-The Effect of the Acidity of the Counterion on Its Solubility and Potential Biopharmaceutical Performance.
He Y; Orton E; Yang D
J Pharm Sci; 2018 Jan; 107(1):419-425. PubMed ID: 29107790
[TBL] [Abstract][Full Text] [Related]
6. Impact of solid state properties on developability assessment of drug candidates.
Huang LF; Tong WQ
Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
[TBL] [Abstract][Full Text] [Related]
7. Effect of counterions on physicochemical properties of prazosin salts.
Kumar L; Meena CL; Pawar YB; Wahlang B; Tikoo K; Jain R; Bansal AK
AAPS PharmSciTech; 2013 Mar; 14(1):141-50. PubMed ID: 23250707
[TBL] [Abstract][Full Text] [Related]
8. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
[TBL] [Abstract][Full Text] [Related]
9. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.
Newman A; Zografi G
J Pharm Sci; 2019 Mar; 108(3):1061-1080. PubMed ID: 30391302
[TBL] [Abstract][Full Text] [Related]
10. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
He Y; Ho C; Yang D; Chen J; Orton E
J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
[TBL] [Abstract][Full Text] [Related]
11. Estimating the maximal solubility advantage of drug salts.
Skrdla PJ
Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
[TBL] [Abstract][Full Text] [Related]
12. Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.
Paulekuhn GS; Dressman JB; Saal C
J Med Chem; 2007 Dec; 50(26):6665-72. PubMed ID: 18052022
[TBL] [Abstract][Full Text] [Related]
13. Effect of counterions on the properties of amorphous atorvastatin salts.
Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.
Bharate SS
Drug Discov Today; 2021 Feb; 26(2):384-398. PubMed ID: 33221522
[TBL] [Abstract][Full Text] [Related]
15. Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".
Korn C; Balbach S
Eur J Pharm Sci; 2014 Jun; 57():257-63. PubMed ID: 24036162
[TBL] [Abstract][Full Text] [Related]
16. Chemical interactions between an active pharmaceutical ingredient and its counterion in a tromethamine salt under forced degradation conditions.
Loeser E; Sutton P; Skorodinsky A; Lin M; Yowell G
Drug Dev Ind Pharm; 2012 Mar; 38(3):357-64. PubMed ID: 22088139
[TBL] [Abstract][Full Text] [Related]
17. Molecular descriptors influencing melting point and their role in classification of solid drugs.
Bergström CA; Norinder U; Luthman K; Artursson P
J Chem Inf Comput Sci; 2003; 43(4):1177-85. PubMed ID: 12870909
[TBL] [Abstract][Full Text] [Related]
18. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
Elder DP; Holm R; Diego HL
Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
[TBL] [Abstract][Full Text] [Related]
19. Preformulation investigation and challenges; salt formation, salt disproportionation and hepatic recirculation.
Sigfridsson K; Nilsson L; Ahlqvist M; Andersson T; Granath AK
Eur J Pharm Sci; 2017 Jun; 104():262-272. PubMed ID: 28366653
[TBL] [Abstract][Full Text] [Related]
20. A case study where pharmaceutical salts were used to address the issue of low in vivo exposure.
Sigfridsson K; Ulvinge ML; Svensson L; Granath AK
Drug Dev Ind Pharm; 2019 Feb; 45(2):202-211. PubMed ID: 30256689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
